{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:33:52Z","timestamp":1762659232102,"version":"build-2065373602"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T00:00:00Z","timestamp":1711756800000},"content-version":"vor","delay-in-days":4016,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Medicine"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.7861\/clinmedicine.13-2-170","type":"journal-article","created":{"date-parts":[[2013,4,4]],"date-time":"2013-04-04T10:41:23Z","timestamp":1365072083000},"page":"170-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recent advancements in the drug treatment of endocrine diseases"],"prefix":"10.1016","volume":"13","author":[{"given":"Amir H","family":"Sam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karim","family":"Meeran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.7861\/clinmedicine.13-2-170_bib1","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"key":"10.7861\/clinmedicine.13-2-170_bib2","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.7861\/clinmedicine.13-2-170_bib3","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.13-2-170_bib4","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with cabergoline and ketoconazole in Cushing\u2019s disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.13-2-170_bib5","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2265.2011.04193.x","article-title":"Acromegaly surgery in Manchester revisited: the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission","volume":"76","author":"Wang","year":"2012","journal-title":"Clin Endocrinol"},{"key":"10.7861\/clinmedicine.13-2-170_bib6","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1210\/jc.2005-2347","article-title":"Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage","volume":"91","author":"Cozzi","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib7","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1172\/JCI39375","article-title":"Acromegaly pathogenesis and treatment","volume":"119","author":"Melmed","year":"2009","journal-title":"J Clin Invest"},{"key":"10.7861\/clinmedicine.13-2-170_bib8","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1210\/jc.2009-2670","article-title":"A consensus on criteria for cure of acromegaly","volume":"95","author":"Giustina","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib9","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1530\/EJE-08-0267","article-title":"A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly","volume":"159","author":"Holdaway","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.7861\/clinmedicine.13-2-170_bib10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib11","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1210\/jc.2008-0027","article-title":"A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly","volume":"93","author":"Murray","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib12","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1210\/jc.2004-2466","article-title":"A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly","volume":"90","author":"Melmed","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib13","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1210\/jc.2005-2110","article-title":"Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients","volume":"91","author":"Colao","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib14","doi-asserted-by":"crossref","first-page":"3746","DOI":"10.1210\/jc.2009-0941","article-title":"Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study","volume":"94","author":"Colao","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib15","first-page":"893","article-title":"Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicenter randomized trial","volume":"72","author":"Thapar","year":"1997","journal-title":"Mayo Clin Proc"},{"key":"10.7861\/clinmedicine.13-2-170_bib16","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1210\/jcem.86.11.7986","article-title":"Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas","volume":"86","author":"Losa","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib17","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/jc.2008-2332","article-title":"Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies","volume":"94","author":"Mazziotti","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib18","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib19","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1056\/NEJM200004203421604","article-title":"Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant","volume":"342","author":"Trainer","year":"2000","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.13-2-170_bib20","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","article-title":"Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY","volume":"97","author":"van der Lely","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib21","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1210\/jc.2004-1967","article-title":"Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly","volume":"90","author":"Jehle","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1210\/jc.2006-1412","article-title":"Gender, body weight, disease activity, and previous radiotherapy influence the response to pegvisomant","volume":"92","author":"Parkinson","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib23","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(05)63011-5","article-title":"Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly","volume":"365","author":"Feenstra","year":"2005","journal-title":"Lancet"},{"key":"10.7861\/clinmedicine.13-2-170_bib25","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1210\/jc.2011-0654","article-title":"Cotreatment with pegvisomant and a somatostatin analog (SA) in SA-responsive acromegalic patients","volume":"96","author":"Madsen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib26","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","article-title":"Selenium and the course of mild Graves\u2019 orbitopathy","volume":"364","author":"Marcocci","year":"2011","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.13-2-170_bib27","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib28","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves\u2019 ophthalmopathy: systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1530\/EJE-08-0874","article-title":"Inadequacies of glucocorticoid replacement and improvements by physiological circadian therapy","volume":"160","author":"Debono","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.7861\/clinmedicine.13-2-170_bib30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1530\/EJE-08-0880","article-title":"Glucocorticoid replacement therapy and pharmacogenetics in Addison\u2019s disease: effects on bone","volume":"160","author":"Lovas","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.7861\/clinmedicine.13-2-170_bib31","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1210\/jc.2012-2432","article-title":"Glucocorticoid replacement and mortality in patients with nonfunctioning pituitary adenoma","volume":"97","author":"Zueger","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2265.2004.02106.x","article-title":"Weight-related dosing, timing and monitoring hydrocortisone replacement therapy in patients with adrenal insufficiency","volume":"61","author":"Mah","year":"2004","journal-title":"Clin Endocrinol"},{"key":"10.7861\/clinmedicine.13-2-170_bib33","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1210\/jc.2009-0032","article-title":"The approach to the adult with newly diagnosed adrenal insufficiency","volume":"94","author":"Arlt","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib34","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/bmj.39588.561840.BD","article-title":"Topiramate can induce hypoadrenalism in patients taking oral corticosteroid replacement","volume":"338","author":"Jacob","year":"2009","journal-title":"BMJ"},{"key":"10.7861\/clinmedicine.13-2-170_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1210\/jc.2011-1926","article-title":"Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation","volume":"97","author":"Johannsson","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib36","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.13-2-170_bib37","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1210\/jc.2010-2784","article-title":"Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk","volume":"96","author":"Boonen","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib38","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"article-title":"Denosumab for the prevention of osteoporotic fractures in postmenopausal women","year":"2010","series-title":"Quick reference guide","key":"10.7861\/clinmedicine.13-2-170_bib39"},{"key":"10.7861\/clinmedicine.13-2-170_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1210\/jc.2009-0358","article-title":"Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women","volume":"95","author":"Cosman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib41","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1210\/jc.2008-1763","article-title":"Guidelines for the management of asymptomatic primary hyperparathyroidism: summary statement from the third international workshop","volume":"94","author":"Bilezikian","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib42","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1210\/jc.2002-021597","article-title":"The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism","volume":"88","author":"Shoback","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib43","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/jc.2004-0842","article-title":"Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism","volume":"90","author":"Peacock","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib44","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1210\/jc.2008-2640","article-title":"Cinacalcet reduces serum calcium concentrations in patients with intractable primary hyperparathyroidism","volume":"94","author":"Marcocci","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib45","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study","volume":"94","author":"Peacock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib46","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.7861\/clinmedicine.13-2-170_bib47","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.13-2-170_bib48","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.13-2-170_bib49","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa063971","article-title":"Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome","volume":"356","author":"Legro","year":"2007","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.13-2-170_bib50","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1210\/jcem.82.4.3900","article-title":"Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)","volume":"82","author":"Saito","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.7861\/clinmedicine.13-2-170_bib51","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N Engl J Med"},{"key":"10.7861\/clinmedicine.13-2-170_bib53","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000106456","article-title":"Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia","volume":"27","author":"Zeltser","year":"2007","journal-title":"Am J Nephrol"},{"key":"10.7861\/clinmedicine.13-2-170_bib54","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/sj.ki.5000432","article-title":"Vasopressin receptor antagonists","volume":"69","author":"Greenberg","year":"2006","journal-title":"Kidney Int"},{"key":"10.7861\/clinmedicine.13-2-170_bib55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.amjmed.2007.09.001","article-title":"Hyponatremia treatment guidelines 2007: expert panel recommendations","volume":"120","author":"Verbalis","year":"2007","journal-title":"Am J Med"},{"key":"10.7861\/clinmedicine.13-2-170_bib24","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2265.2009.03620.x","article-title":"A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly","volume":"71","author":"Trainer","year":"2009","journal-title":"Clin Endocrinol"},{"key":"10.7861\/clinmedicine.13-2-170_bib52","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2215\/CJN.00160106","article-title":"Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist","volume":"1","author":"Soupart","year":"2006","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824016841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1470211824016841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.7861\/clinmedicine.13-2-170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:35:35Z","timestamp":1761460535000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1470211824016841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S1470211824016841"],"URL":"https:\/\/doi.org\/10.7861\/clinmedicine.13-2-170","relation":{},"ISSN":["1470-2118"],"issn-type":[{"type":"print","value":"1470-2118"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recent advancements in the drug treatment of endocrine diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.7861\/clinmedicine.13-2-170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 Royal College of Physicians 2013. All rights reserved.","name":"copyright","label":"Copyright"}]}}